Literature DB >> 22678911

Apoptotic tumor cells induce IL-27 release from human DCs to activate Treg cells that express CD69 and attenuate cytotoxicity.

Divya Sekar1, Christina Hahn, Bernhard Brüne, Edward Roberts, Andreas Weigert.   

Abstract

Intrinsic immunosuppression is a major obstacle for successful cancer therapy. The mechanisms for the induction and regulation of immunosuppression in humans are ill defined. A microenvironmental component that might prevent antitumor immunity is the presence of dying tumor cells, which are abundant following conventional cancer ablation methods such as chemo- or radiotherapy. Shedding of apoptotic debris and/or secretion of factors to the tumor bed or draining lymph nodes thus might have a profound impact on professional phagocytes, such as DCs, and subsequent priming of lymphocytes. Here, we exposed human DCs to supernatants of live, apoptotic, or necrotic human breast cancer cells and cocultured them with autologous T cells. Priming with apoptotic debris prevented DCs from establishing cytotoxicity toward live human tumor cells by inducing a Treg-cell population, defined by coexpression of CD39 and CD69. Immunosuppression via Treg cells was transferable and required the release of sphingosine-1-phosphate (S1P) from apoptotic cells, acting via S1P receptor 4 on DCs to induce IL-27 secretion. We propose that CD69 expression on CD39(+) Treg cells enables them to interact with CD73-expressing CD8(+) T cells to generate adenosine, thereby suppressing cytotoxicity. These findings aid the understanding of how dying tumor cells limit antitumor immunity.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22678911      PMCID: PMC3679920          DOI: 10.1002/eji.201142093

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  59 in total

1.  Isolation and functional use of human NKT cells.

Authors:  Mark A Exley; Brian Wilson; Steven P Balk
Journal:  Curr Protoc Immunol       Date:  2010-08

2.  Decoding cell death signals in inflammation and immunity.

Authors:  Laurence Zitvogel; Oliver Kepp; Guido Kroemer
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

3.  Utilization of the Tango beta-arrestin recruitment technology for cell-based EDG receptor assay development and interrogation.

Authors:  Justin A Wetter; Chetana Revankar; Bonnie J Hanson
Journal:  J Biomol Screen       Date:  2009-09-02

4.  IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10.

Authors:  Irina Kochetkova; Sarah Golden; Kathryn Holderness; Gayle Callis; David W Pascual
Journal:  J Immunol       Date:  2010-05-10       Impact factor: 5.422

5.  Cleavage of sphingosine kinase 2 by caspase-1 provokes its release from apoptotic cells.

Authors:  Andreas Weigert; Sarah Cremer; Martina Victoria Schmidt; Andreas von Knethen; Carlo Angioni; Gerd Geisslinger; Bernhard Brüne
Journal:  Blood       Date:  2010-03-02       Impact factor: 22.113

Review 6.  Cellular vaccine approaches.

Authors:  Dung T Le; Drew M Pardoll; Elizabeth M Jaffee
Journal:  Cancer J       Date:  2010 Jul-Aug       Impact factor: 3.360

7.  Tumor antigen cross-presentation and the dendritic cell: where it all begins?

Authors:  Alison M McDonnell; Bruce W S Robinson; Andrew J Currie
Journal:  Clin Dev Immunol       Date:  2010-10-13

Review 8.  Interleukin 27: a double-edged sword for offense and defense.

Authors:  Hiroki Yoshida; Mako Nakaya; Yoshiyuki Miyazaki
Journal:  J Leukoc Biol       Date:  2009-10-02       Impact factor: 4.962

9.  Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling.

Authors:  Carsten Linnemann; Frank A Schildberg; Anna Schurich; Linda Diehl; Silke I Hegenbarth; Elmar Endl; Svenja Lacher; Christa E Müller; Jürgen Frey; Luca Simeoni; Burkhart Schraven; Dirk Stabenow; Percy A Knolle
Journal:  Immunology       Date:  2009-02-09       Impact factor: 7.397

10.  The supernatant of apoptotic cells causes transcriptional activation of hypoxia-inducible factor-1alpha in macrophages via sphingosine-1-phosphate and transforming growth factor-beta.

Authors:  Barbara Herr; Jie Zhou; Christian Werno; Heidi Menrad; Dmitry Namgaladze; Andreas Weigert; Nathalie Dehne; Bernhard Brüne
Journal:  Blood       Date:  2009-06-23       Impact factor: 22.113

View more
  22 in total

Review 1.  Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states.

Authors:  Maria Serena Longhi; Simon C Robson; Steven H Bernstein; Sara Serra; Silvia Deaglio
Journal:  J Mol Med (Berl)       Date:  2013-01-06       Impact factor: 4.599

2.  Expression of Free Fatty Acid Receptor 2 by Dendritic Cells Prevents Their Expression of Interleukin 27 and Is Required for Maintenance of Mucosal Barrier and Immune Response Against Colorectal Tumors in Mice.

Authors:  Sydney Lavoie; Eunyoung Chun; Sena Bae; Caitlin A Brennan; Carey Ann Gallini Comeau; Jessica K Lang; Monia Michaud; Hamid R Hoveyda; Graeme L Fraser; Miles H Fuller; Brian T Layden; Jonathan N Glickman; Wendy S Garrett
Journal:  Gastroenterology       Date:  2020-01-07       Impact factor: 22.682

Review 3.  The Yin and Yang aspects of IL-27 in induction of cancer-specific T-cell responses and immunotherapy.

Authors:  Ming-Song Li; Zhenzhen Liu; Jin-Qing Liu; Xiaotong Zhu; Zhihao Liu; Xue-Feng Bai
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

4.  The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27.

Authors:  Sènan M d'Almeida; Gilles Kauffenstein; Charlotte Roy; Laetitia Basset; Loukas Papargyris; Daniel Henrion; Véronique Catros; Norbert Ifrah; Philippe Descamps; Anne Croue; Pascale Jeannin; Marc Grégoire; Yves Delneste; Julie Tabiasco
Journal:  Oncoimmunology       Date:  2016-04-28       Impact factor: 8.110

5.  Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy.

Authors:  P Cipriani; P Di Benedetto; V Liakouli; B Del Papa; M Di Padova; M Di Ianni; A Marrelli; E Alesse; R Giacomelli
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

6.  S1PR4 ablation reduces tumor growth and improves chemotherapy via CD8+ T cell expansion.

Authors:  Catherine Olesch; Evelyn Sirait-Fischer; Matthias Berkefeld; Annika F Fink; Rosa M Susen; Birgit Ritter; Birgitta E Michels; Dieter Steinhilber; Florian R Greten; Rajkumar Savai; Kazuhiko Takeda; Bernhard Brüne; Andreas Weigert
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 19.456

7.  MPGES-1-derived PGE2 suppresses CD80 expression on tumor-associated phagocytes to inhibit anti-tumor immune responses in breast cancer.

Authors:  Catherine Olesch; Weixiao Sha; Carlo Angioni; Lisa Katharina Sha; Elias Açaf; Paola Patrignani; Per-Johan Jakobsson; Heinfried H Radeke; Sabine Grösch; Gerd Geisslinger; Andreas von Knethen; Andreas Weigert; Bernhard Brüne
Journal:  Oncotarget       Date:  2015-04-30

8.  Higher Sensitivity of Foxp3+ Treg Compared to Foxp3- Conventional T Cells to TCR-Independent Signals for CD69 Induction.

Authors:  Anna Bremser; Maria Brack; Ana Izcue
Journal:  PLoS One       Date:  2015-09-09       Impact factor: 3.240

Review 9.  Potential clinical application of interleukin-27 as an antitumor agent.

Authors:  Takayuki Yoshimoto; Yukino Chiba; Jun-Ichi Furusawa; Mingli Xu; Ren Tsunoda; Kaname Higuchi; Izuru Mizoguchi
Journal:  Cancer Sci       Date:  2015-08-06       Impact factor: 6.716

10.  Induction of regulatory T cells by high-dose gp96 suppresses murine liver immune hyperactivation.

Authors:  Xinghui Li; Zhen Liu; Xiaoli Yan; Xiaojun Zhang; Yang Li; Bao Zhao; Shengdian Wang; Xuyu Zhou; George F Gao; Songdong Meng
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.